Cobicistat

• A clinical study of people with HIV-1 who take antiretroviral therapy and switch their treatment to a combination of doravirine and islatrav… Not authorised
  2022-502127-22-00 Phase III 3 countries Merck Sharp & Dohme LLC
• A lower dose olaparib, combined with a drug which inhibits olaparib degradation, to increase tolerability and decrease the price of the trea… Recruiting
  2024-516414-38-00 Phase III/IV 1 country Stichting Radboud universitair medisch centrum
• OSIBOOST 2: Improving Osimertinib cost-effectiveness in Non-Small Cell Lung Cancer treatment using dose-modification and pharmacokinetic boo… Recruiting
  2023-505700-35-00 Phase II 1 country University Hospital Maastricht
• A study to investigate the effect of adding cobicistat to venetoclax and azacitidine in patients with acute myeloid leukemia (AML) who are i… Recruiting
  2023-505379-61-00 Phase II 1 country Haemato Oncology Foundation For Adults Netherlands
• A Phase 2 Master Protocol to assess the efficacy and safety of FORE8394, an inhibitor of BRAF Class 1 and Class 2 alterations, in participan… Recruiting
  2024-513578-23-00 Phase II 7 countries Fore Biotherapeutics Inc.
• Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1 ( ISLEND-… Ended
  2024-514047-28-00 Phase III 4 countries Gilead Sciences Inc.

Showing 1–6 of 6 trials